Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
AMES, Iowa, Oct. 1, 2013 /PRNewswire/ -- Ames, Iowa-based vaccine producer, Harrisvaccines, today announced it has been awarded a grant from the USDA National Institute of Food and Agriculture (NIFA) for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) research. This project is supported by Agriculture and Food Research Initiative Grant no. 2013-67015-21307 from the USDA National Institute of Food and Agriculture.
The grant, titled Proteomics-defined Porcine Reproductive and Respiratory Syndrome Virus Immunoproteome, will be a two-year project, beginning on October 1, 2013. Dr. Mark Mogler, Head of Research for Harrisvaccines, and Dr. Kurt Kamrud collaborated in achieving the grant with Dr. Manohar John of PathoVacs. Dr. Mogler will be serving as Project Director.
The basic research project will focus on a new way of looking for protective determinants of the PRRS virus. Harrisvaccines will be generating protein fragment libraries of PRRSV strains and the PRRSV protein fragment libraries will be screened using innovative technology developed by their collaborator on the project, Dr. John.
"Dr. John has a novel technology that allows him to screen thousands of antigens at a time," said Dr. Mogler. "This will be very beneficial, because rather than looking at only one antigen at a time, we will be able to look at tens of thousands simultaneously."
During the first year of the project, Harrisvaccines will be generating the fragments and creating fragment libraries for screening; screening will also be done during the first year. The second year of the project will mainly consist of data analysis and confirmatory testing.
At the end of the two years, Dr. Mogler is confident that Harrisvaccines will be able to characterize the immune response to PRRSV proteins by identifying reactive sites that otherwise, would not have been found.
"Ideally we would find a sequence, or a set of sequences, that are found across all PRRSV strains. We could then use these to make a more effective PRRSV vaccine," Dr. Mogler explained.
Headquartered in Ames, Iowa, Harrisvaccines focuses on revolutionizing animal health vaccines and enhancing productivity in the swine, cattle, equine, and farmed aquaculture industries. Using state-of-the-art advanced molecular science, Harrisvaccines employs their unique SirraVax(SM) RNA Particle (RP) technology platform to develop rapid-response, herd-specific products for animal diseases. To learn more about Harrisvaccines, visit www.harrisvaccines.com.
PathoVacs Incorporated is an early stage Biotechnology Company based in Ames, IA. The Company is based on a highly innovative proteome mining platform for novel protein antigen discovery for development of broadly protective/universal subunit vaccines against infectious agents that cause diseases in humans, livestock and poultry.
©2012 PR Newswire. All Rights Reserved.